Johns Hopkins University
This study aims to assess whether, and the degree to which, ofatumumab modulates or reduces rates of retinal atrophy in people with relapsing-remitting MS (RMS), according to baseline serum neurofilament light chain (sNfL) levels.
Seventy-five people with RMS who due to commence or already receiving ofatumumab therapy within 60 days of baseline will be recruited. All recruited participants will be tracked prospectively over a two-year period. Participants will complete an optical coherence tomography (OCT) scan, visual acuity (VA) assessments, EDSS, and sNfL blood level at baseline and every 6 months. Participants will be tracked prospectively for 2 years. OCT scans, sNfL levels, disability score determinations, 100% high-contrast, 2.5% and 1.25% low-contrast letter acuities will be performed every 6 months. Results fro…
Inclusion Criteria: 1. Between 18 - 70 years of age 2. Have RMS as confirmed by the treating neurologist based on the 2017 revised McDonald criteria AND Either * be due to commence ofatumumab within 60 days of baseline OCT/VA/phlebotomy or * be existing patients attending the center and already receiving ofatumumab, be eligible for inclusion, and already undergoing all of the proposed study procedures. 3. Willing to sign informed consent 4. Willing to undergo phlebotomy Exclusion Criteria: * Uncontrolled Diabetes * Uncontrolled Hypertension * Glaucoma * Refractive errors of +/- 6…
Ofatumumab therapy is part of the patient's clinical care and is not given as part of the study
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.